Viracta Therapeutics (VIRX) News Today → The only accurate crypto trading system I know … (From Weiss Ratings) (Ad) Free VIRX Stock Alerts $0.85 -0.03 (-3.42%) (As of 04/23/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineDay One wins FDA nod for brain cancer therapy, Ojemdamsn.com - April 23 at 3:26 PMPromising Clinical Trial Results Reinforce Buy Rating for Viracta Therapeuticsmarkets.businessinsider.com - April 18 at 7:46 AMViracta Therapeutics (NASDAQ:VIRX) Given "Outperform" Rating at Oppenheimeramericanbankingnews.com - April 18 at 5:30 AMAnalysts Offer Insights on Healthcare Companies: Viracta Therapeutics (VIRX) and UnitedHealth (UNH)markets.businessinsider.com - April 17 at 12:57 PMViracta Therapeutics (NASDAQ:VIRX) Receives Buy Rating from HC Wainwrightamericanbankingnews.com - April 17 at 3:36 AMAnalysts Offer Insights on Healthcare Companies: Icecure Medical (ICCM), Viracta Therapeutics (VIRX) and Bioxcel Therapeutics (BTAI)markets.businessinsider.com - April 16 at 3:51 PMWhy Is Small-Cap Cancer Drug Developer Viracta Therapeutics Stock Trading Lower On Monday?msn.com - April 15 at 1:27 PMViracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphomaglobenewswire.com - April 15 at 8:00 AMViracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwanglobenewswire.com - April 1 at 8:30 AMViracta Therapeutics CFO and COO Dan Chevallard resignsinvesting.com - March 22 at 9:44 PMBuy Rating for Viracta Therapeutics Backed by Upcoming Catalysts and Solid Financialsmarkets.businessinsider.com - March 12 at 2:39 PMVIRX Stock Earnings: Viracta Therapeutics Misses EPS for Q4 2023msn.com - March 8 at 9:38 AMViracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updateglobenewswire.com - March 7 at 4:05 PMViracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trialglobenewswire.com - February 29 at 8:00 AMVIRX Mar 2024 2.500 callfinance.yahoo.com - February 17 at 9:42 AMViracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conferencefinance.yahoo.com - February 6 at 8:23 PMViracta Therapeutics Provides Clinical Update and Outlook for 2024finance.yahoo.com - January 4 at 10:14 AMViracta Therapeutics Stock (NASDAQ:VIRX) Dividends: History, Yield and Datesbenzinga.com - December 22 at 7:49 PMViracta gets orphan drug status for Nana-val for EBV tumorsmsn.com - December 12 at 3:20 PMViracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinomafinance.yahoo.com - December 12 at 10:19 AMViracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levelsfinance.yahoo.com - December 4 at 9:39 AMViracta Therapeutics Inc VIRXmorningstar.com - November 18 at 2:25 PMViracta Therapeutics: Q3 Earnings Insightsbenzinga.com - November 9 at 1:39 PMViracta Therapeutics Inc (VIRX) Reports Q3 2023 Financial Results Amid Clinical Advancesfinance.yahoo.com - November 9 at 1:39 PMViracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - November 9 at 8:38 AMPromising Developments in Viracta Therapeutics Research and Trials Bolster Buy Ratingmarkets.businessinsider.com - October 5 at 7:42 AMViracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated Cancersfinance.yahoo.com - October 4 at 10:22 AMViracta Therapeutics to Host R&D Day on October 4, 2023finance.yahoo.com - September 5 at 5:33 PMViracta Therapeutics, Inc.: Viracta Therapeutics Announces New Employment Inducement Grantfinanznachrichten.de - August 19 at 9:22 AMRBC Capital Reiterates Viracta Therapeutics (VIRX) Outperform Recommendationmsn.com - August 15 at 9:28 PMExpert Ratings for Viracta Therapeuticsmarkets.businessinsider.com - August 15 at 4:28 PMRBC Capital Sticks to Their Buy Rating for Viracta Therapeutics (VIRX)markets.businessinsider.com - August 15 at 9:42 AMViracta Therapeutics (VIRX) Receives a Buy from H.C. Wainwrightmarkets.businessinsider.com - August 15 at 9:42 AMViracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphomafinance.yahoo.com - August 8 at 8:42 AMViracta Therapeutics gets new chief medical officerseekingalpha.com - August 7 at 12:10 PMViracta Therapeutics Names Darrel Cohen Chief Medical Officermarkets.businessinsider.com - August 7 at 12:10 PMViracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officerfinance.yahoo.com - August 7 at 12:10 PMViracta Therapeutics (VIRX) Price Target Decreased by 28.57% to 10.20msn.com - August 3 at 7:32 PMViracta Therapeutics (NASDAQ: VIRX)fool.com - July 19 at 2:25 AMViracta Therapeutics (VIRX) Price Target Decreased by 5.41% to 14.28msn.com - July 6 at 8:11 PMHC Wainwright & Co. Reiterates Viracta Therapeutics (VIRX) Buy Recommendationmsn.com - July 5 at 11:24 PMViracta Therapeutics Says Pivotal Cancer Trial Achieves Efficacy Threshold For Expansion Into Next Stagefinance.yahoo.com - June 28 at 6:34 PMViracta Therapeutics’ Pivotal NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-positive Peripheral T-Cell Lymphoma (R/R EBV+ PTCL)finance.yahoo.com - June 28 at 1:33 PMHC Wainwright & Co. Maintains Viracta Therapeutics (VIRX) Buy Recommendationmsn.com - May 11 at 10:44 PMViracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conferencefinance.yahoo.com - May 11 at 5:44 PMAnalyst Ratings for Viracta Therapeuticsmarkets.businessinsider.com - May 10 at 9:42 PMRBC Capital Maintains Viracta Therapeutics (VIRX) Outperform Recommendationmsn.com - May 9 at 7:15 PMViracta Therapeutics, Inc.: Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updatesfinanznachrichten.de - May 9 at 9:14 AMViracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updatesfinance.yahoo.com - May 8 at 6:11 PMViracta Therapeutics CMO Lisa Rojkjaer, M.D to departseekingalpha.com - May 4 at 8:52 AM Get Viracta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRX and its competitors with MarketBeat's FREE daily newsletter. Email Address The only accurate crypto trading system I know … (Ad)Juan Villaverde is no ordinary crypto trader. His proprietary timing algorithm has led him to rack up a series of gains of 477%, 333% and 153% on Bitcoin … It pointed the way to Cardano, at just 4 cents …Helping investors make 29 times their money. Here's what our expert says you should buy before April 14. VIRX Media Mentions By Week VIRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VIRX News Sentiment▼0.120.45▲Average Medical News Sentiment VIRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VIRX Articles This Week▼71▲VIRX Articles Average Week Get Viracta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SPRB News APM News ENLV News FBRX News LEXX News SLGL News EYEN News ACXP News ALRN News CASI News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VIRX) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersGreat Crypto BullWeiss RatingsThe Next Nvidia?InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viracta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
